Akebia Therapeutics Q2 EPS $(0.06) Misses $(0.02) Estimate, Sales $56.38M Miss $59.10M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics reported Q2 losses of $(0.06) per share, missing the analyst consensus estimate of $(0.02) by 200 percent. This is a 140 percent decrease from the same period last year. The company also reported quarterly sales of $56.38 million, missing the analyst consensus estimate of $59.10 million by 4.61 percent, a 55.53 percent decrease from the same period last year.
August 25, 2023 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Akebia Therapeutics reported a significant miss in both EPS and sales for Q2, indicating a potential negative impact on the stock.
Akebia Therapeutics reported a significant miss in both EPS and sales for Q2. This underperformance is likely to negatively impact investor sentiment and could lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100